Nov. 2, 2023 -- Drug makers Seagen Inc. and Genmab A/S say Phase 3 trial results show a 30% drop in the“Patients with cervical cancer have few treatment options once their cancer comes back or spreads after initial treatment,” said Ignace B. Vergote, MD, co-founder of European Network of Gynaecological Oncological Trial groups and lead investigator in the clinical trial.
“The trial also measured the disease control rate, which is the percentage of patients who experience complete response, partial response or stable disease,” Fox News wrote. “TIVDAK displayed a 75.9% disease control rate, while chemo showed a 58.2% rate.”
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: